Drugs / MK-0736
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00806585 | Dec 2008 → Mar 2010 | hypertensive disorder, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00274716 | Nov 2005 → Jan 2007 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00679055 Comparator | Mar 2007 → Aug 2008 | peripheral vascular disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0736 | “This study evaluated the antihypertensive efficacy and safety of two 11β-HSD1 inhibitors, MK-0736 and MK-0916, in overweight-to-obese hypertensive patients.” PMID 21419745 ↗ Mar 20114“Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)” NCT00806585 ↗ |
| Action | Inhibit | “two 11β-HSD1 inhibitors” PMID 21419745 ↗ Mar 2011 |
| Modality | Small molecule | — CHEMBL1761322 ↗ |
| Route | Oral | “Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks” NCT00679055 ↗ |
| Target | HSD11B1 | “This study evaluated the antihypertensive efficacy and safety of two 11β-HSD1 inhibitors, MK-0736 and MK-0916, in overweight-to-obese hypertensive patients.” PMID 21419745 ↗ Mar 2011 |